Is Tenable Stock a Buy, Sell or Hold?
Tenable (NASDAQ:TENB) is a cybersecurity company with a focus on…
Sell
35
TRDA Quote, Financials, Valuation and Earnings
Last price:
$10.49
Seasonality move
:
1.7%
Day range:
$10.15 - $10.80
52-week range:
$10.15 - $21.79
Dividend yield:
0%
P/E ratio:
5.49x
P/S ratio:
1.92x
P/B ratio:
0.92x
Volume:
205.2K
Avg. volume:
119.5K
1-year change:
-22.53%
Market cap:
$394.4M
Revenue:
$210.8M
EPS (TTM):
$1.91
Analysts' Opinion
-
Consensus RatingEntrada Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $25.43, Entrada Therapeutics has an estimated upside of 142.4% from its current price of $10.49.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $20.00 representing 100% downside risk from its current price of $10.49.
Fair Value
-
According to the consensus of 4 analysts, Entrada Therapeutics has 142.4% upside to fair value with a price target of $25.43 per share.
TRDA vs. S&P 500
-
Over the past 5 trading days, Entrada Therapeutics has underperformed the S&P 500 by -3.45% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Entrada Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Entrada Therapeutics revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Entrada Therapeutics reported revenues of $37.4M.
Earnings Growth
-
Entrada Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Entrada Therapeutics reported earnings per share of $0.03.
Enterprise value:
-25.6M
EV / Invested capital:
-0.06x
Price / LTM sales:
1.92x
EV / EBIT:
-0.55x
EV / Revenue:
-0.12x
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.57x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
-0.50x
Gross Profit (TTM):
--
Return On Assets:
12.42%
Net Income Margin (TTM):
31.14%
Return On Equity:
18.3%
Return On Invested Capital:
18.3%
Operating Margin:
-15.69%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | -- | $129M | $210.8M | $41.8M | $37.4M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$97.2M | -$3.2M | $47M | $4.9M | -$5.9M | |
| EBITDA | -$95.4M | -$321K | $50.8M | $5.6M | -$4.9M | |
| Diluted EPS | -$3.02 | -$0.26 | $1.91 | -$0.29 | $0.03 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $39.9M | $298.7M | $209.9M | $369.8M | $440M | |
| Total Assets | $43.5M | $305.8M | $252.1M | $469.2M | $526.3M | |
| Current Liabilities | $3.4M | $6.7M | $22M | $158.8M | $39.5M | |
| Total Liabilities | $85M | $7.1M | $39.5M | $226.8M | $97.6M | |
| Total Equity | -$41.5M | $298.7M | $212.6M | $242.4M | $428.7M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$93.8M | $139.8M | -$41.6M | -$4M | -$31.6M | |
| Cash From Investing | -$148.7M | -$138.4M | -$27.8M | $19M | $53.4M | |
| Cash From Financing | $479K | $21M | $103M | $690K | $1.4M | |
| Free Cash Flow | -$96.7M | $134.2M | -$44.7M | -$5M | -$32.2M | |
TRDA
Sector
Market Cap
$394.4M
$39.2M
Price % of 52-Week High
48.14%
45.93%
Dividend Yield
0%
0%
Shareholder Yield
-15.33%
-0.81%
1-Year Price Total Return
-22.53%
-38.63%
Beta (5-Year)
--
0.774
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$10.72
200-day SMA
Sell
Level
$15.69
Bollinger Bands (100)
Sell
Level
12.25 - 18.83
Chaikin Money Flow
Sell
Level
-2.3M
20-day SMA
Sell
Level
$11.24
Relative Strength Index (RSI14)
Sell
Level
35.62
ADX Line
Sell
Level
31.28
Williams %R
Neutral
Level
-74.6269
50-day SMA
Sell
Level
$12.58
MACD (12, 26)
Sell
Level
-0.70
25-day Aroon Oscillator
Sell
Level
-76
On Balance Volume
Neutral
Level
2.9M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (5.2565)
Buy
CA Score
(Annual)
Level (0.9257)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (4)
Buy
Ohlson Score
Level (-4.2543)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company’s Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.
Stock Forecast FAQ
In the current month, TRDA has received 4 Buy ratings 0 Hold ratings, and 0 Sell ratings. The TRDA average analyst price target in the past 3 months is $25.43.
-
Where Will Entrada Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Entrada Therapeutics share price will rise to $25.43 per share over the next 12 months.
-
What Do Analysts Say About Entrada Therapeutics?
Analysts are divided on their view about Entrada Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Entrada Therapeutics is a Sell and believe this share price will drop from its current level to $20.00.
-
What Is Entrada Therapeutics's Price Target?
The price target for Entrada Therapeutics over the next 1-year time period is forecast to be $25.43 according to 4 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is TRDA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Entrada Therapeutics is a Buy. 4 of 4 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of TRDA?
You can purchase shares of Entrada Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Entrada Therapeutics shares.
-
What Is The Entrada Therapeutics Share Price Today?
Entrada Therapeutics was last trading at $10.49 per share. This represents the most recent stock quote for Entrada Therapeutics. Yesterday, Entrada Therapeutics closed at $10.49 per share.
-
How To Buy Entrada Therapeutics Stock Online?
In order to purchase Entrada Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is CyberArk Stock a Buy, Sell or Hold?
CyberArk Software (NASDAQ:CYBR), the identity security and management firm, has…
Is Amazon Stock Still Worth Staking On?
Amazon.com Inc (NASDAQ: AMZN) posted one of its strongest years…
Stock Ideas
Buy
55
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 36x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
51
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 40x
Alerts
Sell
50
RGC alert for Mar 22
Regencell Bioscience Holdings [RGC] is up 27.82% over the past day.
Sell
36
VMI alert for Mar 22
Valmont Industries [VMI] is down 12.54% over the past day.
Buy
61
ALNY alert for Mar 22
Alnylam Pharmaceuticals [ALNY] is up 11.7% over the past day.
